On February 26, 2019 Selexis SA and Turgut Pharmaceuticals (Turgut Ilaclari AS) reported that they have signed two trademark license agreements (CLMs) through which Turgut will operate the SURE Technology Platform and SURE CHO-M Cell Line by Selexis for the development of two high-end biosimilar antibodies: a control point inhibitor for the treatment of certain cancers and a monoclonal antibody for the treatment of HER2-positive metastatic breast cancer (Press release, Selexis FEB 26, 2019, View Source [SID1234533699]). With the addition of these CLMs, companies are now collaborating on the development of multiple biosimilars for cancer and inflammatory diseases. The companies announced the signing of the most recent CLMs in December 2017 .
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"In just under three years, we have signed five brand license agreements, in collaboration with the Turgut team, to advance its high-end biosimilar pipeline. Our technology and our cell line have proven their impact on biosimilar development, which is very important given the huge demand to offer patients expanded access to life-changing organic products, "said Marco Bocci., PhD at DPharm, Vice President of Licensing and Business Development at Selexis. "Turgut shares our passion for bringing advanced medicines to patients faster and at a lower cost. The success we have had with Turgut so far has been fueled by our collaboration and we are very pleased to continue supporting their efforts to bring biosimilars to the market under these new licenses. "
Selexis’ proprietary SURE technology platform facilitates the rapid, stable and cost-effective production of virtually all recombinant proteins, including biosimilars, and provides a seamless integration of the organic product development continuum, from discovery to commercialization. Using the SURE technology platform, Selexis has managed to generate many biosimilars, including marketed products, whose glycan profiles correspond to the originator drugs.
"These two products are innovative treatments that can improve accessibility for a much larger patient population," said Serdar Alpan, MD, PhD, head of the Biotechnology Group at Turgut Pharmaceuticals. "As a cell line development specialist and Turgut’s strong partner, Selexis’ tools and technologies provide us with the competitiveness we need to move forward on our biosimilar programs. We look forward to moving these programs forward. "
The SURE CHO-M cell line from Selexis is a high performance mammalian cell line derived from CHO-K1 cells and used for the production of recombinant therapeutic proteins and monoclonal antibodies. The growth and production properties of the Selexis SURE CHO-M cell line are well defined and the feeding strategy has been optimized to allow for faster and more efficient scaling of the bioreactors. Therapies generated with Selexis SURE CHO-M cells undergo clinical trials and are transformed into marketed products.